留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

PET组合融合成像在分化型甲状腺癌复发和转移中的应用进展

杨立光,  刘新疆

downloadPDF
文章导航 > 分子影像学杂志  > 2020 >  43(1): 49-52
杨立光, 刘新疆. PET组合融合成像在分化型甲状腺癌复发和转移中的应用进展[J]. 分子影像学杂志, 2020, 43(1): 49-52. doi: 10.12122/j.issn.1674-4500.2020.01.11
引用本文: 杨立光, 刘新疆. PET组合融合成像在分化型甲状腺癌复发和转移中的应用进展[J]. 分子影像学杂志, 2020, 43(1): 49-52. doi: 10.12122/j.issn.1674-4500.2020.01.11
shu
Liguang YANG, Xinjiang LIU. Application progress of PET combined fusion imaging in the recurrence and metastasis of differentiated thyroid cancer[J]. Journal of Molecular Imaging, 2020, 43(1): 49-52. doi: 10.12122/j.issn.1674-4500.2020.01.11
Citation: Liguang YANG, Xinjiang LIU. Application progress of PET combined fusion imaging in the recurrence and metastasis of differentiated thyroid cancer[J]. Journal of Molecular Imaging, 2020, 43(1): 49-52. doi: 10.12122/j.issn.1674-4500.2020.01.11
shu

PET组合融合成像在分化型甲状腺癌复发和转移中的应用进展

doi: 10.12122/j.issn.1674-4500.2020.01.11
  • 1.

    滨州医学院附属医院放射科，山东  滨州  256600

  • 2.

    上海市浦东医院（复旦大学附属浦东医院）放射科，上海 201300

详细信息
    作者简介:

    杨立光，硕士研究生，住院医师，E-mail：ylg1013@163.com

    通讯作者:

    刘新疆，博士，主任医师，E-mail：lxj6513@163.com

Application progress of PET combined fusion imaging in the recurrence and metastasis of differentiated thyroid cancer

  • 1.

    Departmen of Radiology, Affiliated Hospital of Binzhou Medical University, Binzhou 256600, China

  • 2.

    Department of Radiology, Shanghai Pudong Hospital（Fudan University Pudong Medical Center）, Shanghai 201300, China

    摘要
  • 摘要: 甲状腺癌是最常见的内分泌系统恶性肿瘤之一，其中分化型甲状腺癌约占甲状腺癌发病率的90%以上，预后良好。但中国甲状腺癌患者5年相对生存率与一些发达国家差距较大。早期、准确地发现复发性疾病并应用适当的治疗策略，可改善复发性疾病患者的预后。因此，早期发现这些病人的复发和转移是至关重要的。随着诊断技术从系统向分子水平的过渡，多模态分子成像的作用越来越重要。PET能提供肿瘤细胞的功能学信息，而CT、MRI则能提供肿瘤的解剖学信息。功能成像技术和解剖学成像技术相结合能够实现优势互补，对于疾病复发和转移的诊断意义重大。随着近年来PET-CT在分化型甲状腺癌诊断、分期、疗效及预后评估上都较常规影像学检查更具优势，而PET-MRI是继PET-CT之后又一项优秀的多模态成像技术，因其软组织高分辨率和多序列多参数成像特性，所发挥的作用也愈发重要。因此，本文就PET-CT和PET-MRI在分化型甲状腺癌术后复发/转移中临床应用及未来前景进行综述。

     

    Abstract: Thyroid cancer is one of the most common endocrine system malignancies, in which differentiated thyroid cancer accounts for more than 90% of the incidence of thyroid cancer, with a good prognosis. However, the 5-year relative survival rate of thyroid cancer patients in China is far from that in some developed countries. Early and accurate detection of recurrent disease and appropriate treatment strategies can improve the prognosis of patients with recurrent disease. Therefore, early detection of recurrence and metastasis of these patients is essential. With the transition of diagnostic technology from system to molecular level, multi-modal molecular imaging is increasingly important. PET can provide functional information of tumor cells, while CT and MRI can provide anatomical information of tumors.The combination of functional imaging technology and anatomical imaging technology can achieve complementary advantages and is of great significance for the diagnosis of disease recurrence and metastasis. Two major directions of combined PET fusion imaging are PET-CT and PET-MRI. In recent years, PET-CT has more advantages than conventional imaging in the efficacy and prognosis evaluation of DTC diagnosis staging, and PET-MRI is another excellent multi-mode imaging technology after PET-CT. Due to its high-resolution soft tissue and multi-sequence and multi-parameter imaging characteristics, PET-MRI is increasingly important. Therefore, the clinical application and future prospect of PET-CT and PET-MRI in postoperative recurrence/metastasis of differentiated thyroid cancer is reviewed.

     

    • HTML全文
    • 参考文献(36)
  • [1] Ling BD, Runhua L, Ming HG, et al. Incidence and mortality of thyroid cancer in China, 2008-2012[J]. Chin J Cancer Res, 2019, 31(1): 144-51. doi: 10.21147/j.issn.1000-9604.2019.01.09
    [2] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005
    [3] 曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(3): 145-9. doi: 10.3969/j.issn.1000-8179.2019.03.283
    [4] 严 威, 黄芸谦, 陈 乔, 等. 美国放射学会TI-RADS在甲状腺癌中的应用价值[J]. 肿瘤影像学, 2019, 28(1): 17-20. doi: 10.3969/j.issn.1008-617X.2019.01.004
    [5] Haugen BR. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed[J]. Cancer, 2017, 123(3): 372-81. doi: 10.1002/cncr.30360
    [6] Mueh G, Karp JS. Positron emission tomography imaging--technical considerations[J]. Semin Nucl Med, 1986, 16(1): 35-50. doi: 10.1016/S0001-2998(86)80003-4
    [7] 董丽华, 陈 翼, 罗 霞. PET显像仪临床应用的广泛性与局限性分析[J]. 西南军医, 2010, 12(3): 475-6. doi: 10.3969/j.issn.1672-7193.2010.03.034
    [8] 安程程, 张卫健, 朱金海, 等. 多灶性甲状腺乳头状癌的临床病理特点及颈部淋巴结转移规律[J]. 分子影像学杂志, 2019, 42(4): 490-4.
    [9] 周丽丽, 郑 旋, 彭友霖. PET-CT的成像原理及其临床应用[J]. 系统医学, 2017, 2(2): 162-4.
    [10] 徐金锴. Tg变化对甲状腺癌转移性淋巴结检测特异性分析[J]. 现代医学, 2017, 45(8): 1076-9.
    [11] Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: thyroid carcinoma, version 2[J]. J Natl Compr Canc Netw, 2018, 16(12): 1429-40. doi: 10.6004/jnccn.2018.0089
    [12] Larg MI, Barnus E, Gabora K, et al. 18F-FDG PET/CT in differentiated thyroid carcinoma[J]. Acta Endocrinol (Buchar), 2019, 15(2): 203-8. doi: 10.4183/aeb.2019.203
    [13] Doner RK, Sager S, Gortan FA, et al. What is the role of florine-18 fluorodeoxyglucose/positron emission tomography/computed tomography imaging in well-differentiated thyroid cancers with negative iodine-131 scan high thyroglobulin and normal anti-thyroglobulin levels[J]. J Cancer Res Ther, 2016, 12(2): 1010-7. doi: 10.4103/0973-1482.176412
    [14] 刘日信, 曾凤伟, 李建芳, 等. 分化型甲状腺癌~(131)I治疗后早期TgAb变化幅度与疗效的关系[J]. 临床与病理杂志, 2019, 39(6): 1215-9. doi: 10.3978/j.issn.2095-6959.2019.06.010
    [15] Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation[J]. Clin Endocrinol (Oxf), 2002, 57(2): 215-21. doi: 10.1046/j.1365-2265.2002.01592.x
    [16] Zhong L, Liu J, Zhou J, et al. Serum proteomics study reveals candidate biomarkers for systemic lupus erythematosus[J]. Int J Clin Exp Pathol, 2017, 10(10): 10681-94.
    [17] 胡小巧, 郭炳君, 陈晓品. PET-CT在恶性肿瘤治疗后评价中的作用与局限性[J]. 现代肿瘤医学, 2015, 23(15): 2239-42. doi: 10.3969/j.issm.1672-4992.2015.16.49
    [18] 陈 钊, 郑 容, 吴 宁. (18)F-FDG PET-CT的主要局限性和相应处理措施[J]. 中国医学影像技术, 2006, 16(2): 320-3. doi: 10.3321/j.issn:1003-3289.2006.02.050
    [19] Furuta A, Onishi H, Kangai Y, et al. Effect of scatter limitation correction with misregistration between computed tomography and positron emission tomography on scatter correction: a physical phantom study[J]. Nihon Hoshasen Gijutsu Gakkai Zasshi, 2017, 73(3): 185-93. doi: 10.6009/jjrt.2017_JSRT_73.3.185
    [20] 祝安惠, 张燕燕. 一体化PET/MR应用进展[J]. 中国介入影像与治疗学, 2018, 15(1): 51-4.
    [21] 曾天翼, 宋少莉, 吕力琅. 一体化PET/MR技术的发展及临床应用[J]. 肿瘤影像学, 2019, 28(4): 276-82.
    [22] Galgano SJ, Marshall RV, Midd EH, et al. PET/MR imaging in head and neck cancer: current applications and future directions[J]. Magn Reson Imaging Clin N Am, 2018, 26(1): 167-78. doi: 10.1016/j.mric.2017.08.010
    [23] Delso G, Furst S, Jakoby B, et al. Performance measurements of the siemens mMR integrated whole-body PET/MR scanner[J]. J Nucl Med, 2011, 52(12): 1914-22. doi: 10.2967/jnumed.111.092726
    [24] Czernin J, Herr K. The potential of PET/MRI imaging in oncology: a comment to a summary report of the first PET/MRI workshop in tuebingen in 2012[J]. Mol Imaging Biol, 2013, 15(4): 372-3. doi: 10.1007/s11307-013-0642-y
    [25] Czernin J, TA L, Herr K. Does PET/MR Imaging improve cancer assessments? literature evidence from more than 900 patients[J]. J Nucl Med, 2014, 55(Supplement 2): 59S-62S.
    [26] Jent W, Phao J, Gomez B, et al. Quantitative performance of (124)I PET/MR of neck lesions in thyroid cancer patients using (124)I PET/CT as reference[J]. Ejnmm Phys, 2018, 5(1): 13-22. doi: 10.1186/s40658-018-0214-y
    [27] Barbosa FG, von Shul G, Veit P. Workflow in simultaneous PET/MRI[J]. Semin Nucl Med, 2015, 45(4): 332-44. doi: 10.1053/j.semnuclmed.2015.03.007
    [28] Wuerts R, Jent W, Quick HH, et al. Quantitative performance evaluation of (124)I PET/MRI lesion dosimetry in differentiated thyroid cancer[J]. Phys Med Biol, 2017, 63(1): 15014-25. doi: 10.1088/1361-6560/aa990b
    [29] Seibo L, Van Nostrand D, Wartof L, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer[J]. Thyroid, 2008, 18(2): 103-11. doi: 10.1089/thy.2007.0135
    [30] 张 乐, 郭 宏, 白人驹. 多示踪剂PET/PET-CT显像在肺癌诊断中的价值[J]. 国际医学放射学杂志, 2012, 35(01): 43-6. doi: 10.3784/j.issn.1674-1897.2012.01.Z0109
    [31] Kuker R, Sztejin M, Gulec S. I-124 imaging and dosimetry[J]. Mol Imaging Radionucl Ther, 2017, 26(Suppl 1): 66-73.
    [32] Santh P, Taieb D, Solnes L, et al. Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2017, 86(5): 645-51. doi: 10.1111/cen.13306
    [33] Lutje S, Gomez B, Cohnen J, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68 Ga-HBED-CC-PSMA PET/CT[J]. Clin Nucl Med, 2017, 42(1): 20-5. doi: 10.1097/RLU.0000000000001454
    [34] Wener M, Binse I, Nagar J, et al. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer[J]. Q J Nucl Med Mol Imaging, 2019, 63(3): 235-52.
    [35] Vrach A, Burg MC, Wenning C, et al. [(18)F]FDG PET/CT outperforms[(18)F]FDG PET/MRI in differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43(2): 212-20. doi: 10.1007/s00259-015-3195-2
    [36] 刘 冰, 范丽娟, 凌 坚, 等. 甲状腺癌磁共振成像及发展状况[J]. 医疗装备, 2019, 32(5): 196-9. doi: 10.3969/j.issn.1002-2376.2019.05.126
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  958
  • HTML全文浏览量:  432
  • PDF下载量:  23
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-01-29
  • 刊出日期:  2020-01-01

目录

    /

    返回文章
    返回
    • 版权所有© 2013《分子影像学杂志》编辑部 ICP备00000000号
    • 重点提示: Adobe Reader6可能造成全文显示不正常，请升级为Adobe Reader7或更高。
    • 地址: 广东省广州市广州大道北1838号 Tel: 020-61648176 E-mail: 

    本系统由 北京仁和汇智信息技术有限公司 开发  技术支持：info@rhhz.net

    x 关闭 永久关闭

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者：

    为了缩短出版时滞，促进科研成果的快速传播，我刊自2024年1月起，刊期由双月刊变更为月刊。本刊主要栏目有：基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱！

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日